AstraZeneca’s COVID-19 vaccine poses a small risk of rare blood clots with low platelets after the first dose which reduces significantly after the second dose.
According to a recently published study, the estimated rate of Thrombosis with Thrombocytopenia Syndrome (TTS) after the first dose of AstraZeneca’s vaccine is 8.1 per million which comes down to 2.3 per million after the second dose.
In an official statement, the UK-based pharmaceutical company said that the benefits of AstraZeneca’s vaccine in preventing COVID-19 infection and its complications continue to outweigh any risks.
AstraZeneca has faced several setbacks including production delays and rare cases of severe side effects this year. This caused several countries to restrict or stop the use of the vaccine and forced healthcare regulators to launch probes and change warning labels of the vaccine.
In April this year, European Union (EU) initiated legal action against AstraZeneca, for delaying the shipment of hundreds of millions of doses of its COVID-19 vaccine to the 27-nation bloc.
A month earlier, more than a dozen countries, mostly in Europe, suspended the use of the vaccine as a precautionary measure after a number of recipients suffered rare blood clots in the days and weeks that followed.